Agenus Inc. Share Price
NASDAQ: AGEN | Micro CapAgenus Inc. Stock Performance
Open $7.51 | Prev. Close $7.48 | Circuit Range N/A |
Day Range $6.92 - $7.51 | Year Range $2.73 - $8.65 | Volume 32,176 |
Average Traded $7.13 |
Agenus Inc. Share Price Today
As of 10 August 2026, Agenus Inc.'s share price is $6.95. The stock opened at $7.51, compared to its previous close of $7.48. During today's trading session, Agenus Inc.'s share price traded between $6.92 and $7.51, with an average price of $7.22. Over the past 52 weeks, the stock has recorded a high of $8.65 and a low of $2.73. In terms of performance, Agenus Inc.'s share price has risen by 108.56% over the last six months and is up 65.95% on a year-on-year basis.
Agenus Inc. Share Price Chart
Agenus Inc. Stock Fundamentals & Key Indicators
Market Cap $206.50M | PE Ratio (TTM) N/A | Dividend Yield N/A |
EPS (TTM) $0.00 | Revenue (TTM) $114.20M | Return On Equity (TTM) 1.14% |
Profit Margin -2.70% | Debt to Equity -1.19 | Quarterly Earnings Growth YoY N/A |
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $7.62 | $6.95 | -7.40% |
Jul 2026 | $3.10 | $7.50 | +146.31% |
Jun 2026 | $3.51 | $3.04 | -12.75% |
May 2026 | $3.81 | $3.49 | -10.63% |
Apr 2026 | $3.43 | $3.90 | +16.57% |
Mar 2026 | $3.27 | $3.35 | +0.60% |
Feb 2026 | $2.92 | $3.33 | +17.67% |
Jan 2026 | $3.15 | $2.83 | -9.73% |
Dec 2025 | $4.47 | $3.13 | -30.95% |
Nov 2025 | $3.96 | $4.54 | +14.65% |
Oct 2025 | $3.94 | $3.96 | +2.59% |
Sep 2025 | $4.12 | $3.86 | -7.77% |
AGEN Share Price FAQs
What is Agenus Inc. share price today?
What is the 52 week high and 52 week low of Agenus Inc. stock?
What is AGEN's market capitalisation today?
What is the 5 year returns of AGEN?
What is the high & low stock price of AGEN today?
Can I buy AGEN shares in India?